title: [The peptide mapping of the E2-2 and E2-6 sites of the E2 glycoprotein in the Venezuelan equine encephalomyelitis virus].
abstract: Nine peptides were synthesized for detailed mapping of VEE virus E2-2 and E2-6 sites responsible for the formation of protective antibodies that neutralize the virus and block hemagglutination. The sequence of the peptides over-lapped the regions of amino acid residues 30-75 and 202-250 of VEE virus E2 protein in which antigenic mutations caused by monoclonal antibodies to E2-2 and E2-6 sites had been mapped. None of the synthesized peptides reacted in the enzyme immunoassay with a panel of 17 Mabs to VEE virus E2 protein. However, eight peptides reacted with polyclonal antiviral serum and two of them elicited antiviral antibody production. The E2-2 site might be associated with amino acid residues 30-45, and the region of E2 residues 57-62 in which antigenic mutations are observed is not a linear type antigenic determinant, but participates in the formation of antigenic determinants of the conformational type. The mapping of residues 202-250 demonstrated that all the peptides in this region were well recognized by polyclonal antiviral serum. The residues 235-240 were shown to form a linear epitope which provided a crossover between VEE and EEE viruses and was not recognized by 19 types of monoclonal antibodies cross-reacting with VEE and EEE viruses.
authors.forename: V A
authors.initials: VA
authors.lastname: Sviatchenko
authors.forename: A V
authors.initials: AV
authors.lastname: Pereboev
authors.forename: E V
authors.initials: EV
authors.lastname: Agapov
authors.forename: I A
authors.initials: IA
authors.lastname: Razumov
authors.forename: A N
authors.initials: AN
authors.lastname: Sabirov
authors.forename: G A
authors.initials: GA
authors.lastname: Mizenko
authors.forename: V V
authors.initials: VV
authors.lastname: Samukov
authors.forename: V B
authors.initials: VB
authors.lastname: Loktev
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000302:isolation & purification; D000956:Antigens, Viral / Q000032:analysis / Q000276:immunology; D001666:Binding Sites, Antibody / Q000276:immunology*; D004666:Encephalitis Virus, Venezuelan Equine / Q000737:chemistry* / Q000276:immunology; D000939:Epitopes / Q000032:analysis / Q000276:immunology; D006825:Hybridomas / Q000276:immunology; D007114:Immunization; D007158:Immunologic Techniques; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009154:Mutation / Q000276:immunology; D010449:Peptide Mapping / Q000379:methods*; D010455:Peptides / Q000138:chemical synthesis; D051381:Rats; D014759:Viral Envelope Proteins / Q000032:analysis* / Q000276:immunology; D014760:Viral Fusion Proteins / Q000032:analysis* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000956:Antigens, Viral; D000939:Epitopes; D010455:Peptides; D014759:Viral Envelope Proteins; D014760:Viral Fusion Proteins; C064956:glycoprotein E2, equine encephalitis virus